
ESOCAP RECEIVES PATENT IN ISRAEL FOR GLOBAL FIRST LOCAL ESOPHAGEAL THERAPEUTIC APPLICATION



EsoCap

Basel, Switzerland, July 28, 2021

EsoCap announced today that the novelty of their unique drug delivery technology has once again been confirmed by a patent, granted by the State of Israel, under number 252893, based on patent application PCT/EP/2015/002601.

So far there is no effective local treatment for diseases of the esophagus due to the ultra-short transit time of convenient drug formulations. This will change with the unique targeted application platform developed by EsoCap together with the University Greifswald, a research partner highly valued and experienced in this field.

EsoCap already owns several patents in the US, Japan and Australia, for example. The flexible drug delivery platform with combination potential covers a range from small molecules to biologicals, including approved active pharmaceutical ingredients (APIs) and APIs under development.

“Our technology offers treatment for a broad range of diseases with treatment options that, up until now, have been dissatisfying”, confirms Isabelle Racamier, CEO of EsoCap AG, who continues “Moreover, our technology is the treatment of choice for several high-value esophageal indications.”

“The industrial scale-up process has been initiated with established industry partners”, points out Dr. Peter Stangier, EsoCap AG’s Director Strategic Planning, adding “More importantly, we recently entered a phase II trial in Europe and expect it to validate clinically the efficacy of our technology as potential game changer.”

About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through the development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short contact time of drugs, of one to two seconds, from the mouth to the stomach.

EsoCap owns and develops a unique drug delivery platform allowing efficient topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocap-biotech.com.

Contact:

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com